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Abstract
We report an efficient therapeutic modality for platinum resistant ovarian cancer based on siRNA-
mediated suppression of a multifunctional DJ-1 protein that is responsible for the proliferation, 
growth, invasion, oxidative stress and overall survival of various cancers. The developed 
therapeutic strategy can work alone or in concert with a low dose of the first line chemotherapeutic 
agent cisplatin, to elicit a maximal therapeutic response. To achieve an efficient DJ-1 knockdown, 
we constructed the polypropylenimine dendrimer-based nanoplatform targeted to LHRH receptors 
overexpressed on ovarian cancer cells. The quantitative PCR and western immunoblotting 
analysis, revealed that the delivered DJ-1 siRNA downregulated the expression of targeted mRNA 
and corresponding protein by more than 80% in various ovarian cancer cells. It was further 
demonstrated that siRNA-mediated DJ-1 suppression dramatically impaired proliferation, viability 
and migration of the employed ovarian cancer cells. Finally, the combinatorial approach led to the 
most pronounced therapeutic response in all the studied cell lines, outperforming both siRNA-
mediated DJ-1 knockdown and cisplatin treatment alone. It is noteworthy that the platinum-
resistant cancer cells (A2780/CDDP) with the highest basal level of DJ-1 protein are most 
susceptible to the developed therapy and this susceptibility declines with decreasing basal levels of 
DJ-1. Finally, we interrogate the molecular underpinnings of the DJ-1 knockdown effects in the 
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treatment of the ovarian cancer cells. By using various experimental techniques, it was revealed 
that DJ-1 depletion: (1) decreases the activity of the Akt pathway, thereby reducing cellular 
proliferation, migration and increasing the antiproliferative effect of cisplatin on ovarian cancer 
cells; (2) enhances the activity of p53 tumor suppressor protein therefore restoring cell cycle arrest 
functionality and upregulating the Bax-caspase pathway, triggering cell death; and (3) weakens the 
cellular defense mechanisms against inherited oxidative stress thereby increasing toxic 
intracellular radicals and amplifying the reactive oxygen species created by the administration of 
cisplatin.
Graphical Abstract
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INTRODUCTION
Ovarian cancer kills over 14,000 women every year in the United States alone and is known 
as the “silent killer” due to the fact that very few symptoms are present until the later stages 
of the disease’s development.1 Treatment options for advanced stage ovarian cancer are 
limited and consist primarily of maximal debulking surgery followed by chemotherapy.2 The 
main problem of cytoreductive surgery is related to the fact that it cannot provide complete 
cancer resection and the need to administer chemotherapy post-surgery is of the utmost 
importance to reduce ovarian cancer recurrence.3, 4 A combined chemotherapy regimen, 
which involves two or more chemotherapeutic drugs such as platinum- or taxane-based 
agents, has been shown to be most beneficial when treating ovarian cancer, as it targets 
multiple cancer progression pathways.5, 6 The efficacy of conventional chemotherapy, 
however, is limited by the aggressive nature of the ovarian cancer cells as well as their 
ability to upregulate specific proteins responsible for multidrug resistance.7 Moreover, a 
drawback of the current combinatorial chemotherapy is an increase of systemic side effects 
when several drugs are added to the regimen.6 The adverse side effects in healthy organs 
invariably impose dose reduction of chemotherapeutic drugs or even discontinuance of 
therapy. Hence, there is a need to develop a novel therapeutic approach that can work alone 
or in concert with a low dose of a single chemotherapeutic drug to elicit a maximal 
therapeutic response while minimizing the risk of physically detrimental side effects.
Recently DJ-1, also known as PARK7, has been identified as an oncogenic driver and a 
significant amount of experimental evidences has indicated that it is frequently 
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overexpressed in various human cancers, including prostate cancer, non-small cell lung 
carcinoma, pancreatic ductal adenocarcinoma, and ovarian carcinoma.8, 9 It has been also 
demonstrated that higher DJ-1 expression is positively associated with decreased survival in 
patients with various tumor types including non-small cell lung cancer, esophageal 
squamous cell carcinoma and ovarian cancer.10–12 DJ-1 is a multifaceted protein and to date 
it has been found to be responsible for the proliferation, growth, invasion, and overall 
survival of various cancers.9 DJ-1 is known to affect several cellular processes that drive 
cancer progression (Figure 1). These processes include: (1) Proliferation, where DJ-1 
inhibits the actions of phosphatase and tensin homolog (PTEN) allowing the Akt 
proliferation pathway to proceed forward unchecked (Figure 1A);9, 13, 14 (2) Apoptosis and 
cell cycle arrest, wherein DJ-1 binds to tumor protein p53 and inhibits its translocation to the 
nucleus, thereby preventing enhanced expression of various anti-apoptotic proteins, as well 
as p53’s ability to arrest cell cycle progression (Figure 1B);9, 15 (3) Oxidative stress 
responses, DJ-1 can directly scavenge reactive oxygen species (ROS), as well as enhance 
synthesis of reduced glutathione (GSH), and influence the destabilization of the NRF2/
Keap1 complex, thus allowing transcriptional factor NRF2 to accumulate in the nucleus, and 
upregulate expression of multiple antioxidant proteins (Figure 1C). 16, 17 Additionally, DJ-1 
has been identified as a cisplatin (CDDP) resistant biomarker in both non-small cell lung 
cancer and pancreatic cancer, making DJ-1 a potentially important therapeutic target for the 
treatment of DJ-1 overexpressing platinum resistant ovarian cancer.1812 Finally, several 
studies reported that an increase in cytosolic DJ-1 is negatively correlated with overall 
ovarian cancer cell survival.9, 10
Based on the aforementioned facts, it has been hypothesized that siRNA-mediated silencing 
of DJ-1 protein in combination with CDDP as a first line chemotherapeutic agent, 19 can 
result in enhanced therapeutic efficacy for ovarian cancer while minimizing adverse side 
effects. To verify the proposed hypothesis and achieve an efficient and targeted delivery of 
DJ-1 siRNA to various ovarian cancer cells, we constructed a nanoparticle-based siRNA 
delivery system, which contains four components (Figure 2): (1) siRNA molecules to 
attenuate DJ-1 gene expression; (2) Polypropylenimine (PPI) dendrimer to act as a siRNA 
carrier; (3) polyethylene glycol (PEG) to enhance stability and biocompatibility of the 
nanoplatform; and (4) LHRH peptide, serving as a specific targeting moiety to ovarian 
cancer cells.20 By incorporating the prepared siRNA nanoplatform (siRNA-NP) and the first 
line chemotherapeutic agent CDDP, we have developed an efficient combinatorial 
therapeutic approach for the treatment of platinum-resistant ovarian cancer cells and 
elucidate the underlying role of the DJ-1 protein in ovarian cancer cells survival and growth. 
Herein, we provide evidence for the abrogation of the platinum resistant phenotype of 
several ovarian cancer cell lines via the suppression of DJ-1 protein. Our report relies on 
three major observations: DJ-1 depletion (1) decreases the activity of the Akt pathway, 
thereby reducing cellular proliferation, migration, and increasing the antiproliferative effect 
of CDDP on ovarian cancer cells; (2) enhances the activity of p53 tumor suppressor protein 
therefore restoring cell cycle arrest functionality and upregulating the Bax-caspase pathway, 
triggering cell death; (3) weakens cellular ROS defense mechanisms thereby increasing toxic 
intracellular radicals and amplifying the ROS created by the administration of CDDP.
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MATERIALS AND METHODS
Materials
Human ovarian carcinoma A2780/CDDP, ES2, IGROV1 and SKOV3 cell lines were 
purchased form ATCC (Manassas, VA). Generation 4 poly(propylene imine) dendrimer 
(PPIG4) was obtained from SyMO-Chem (The Netherlands). Luteinizing Hormone 
Releasing Hormone (LHRH) peptide (Gln-His-Trp-Ser-Tyr-DLys(DCys)-Leu-Arg-Pro-NH-
Et) was purchased from Amersham Peptide Co. (Sunnyvale, CA). α-Maleimide-ω-N-
hydroxysuccinimide ester poly(ethylene glycol) (MAL-PEG-NHS 5 kDa) was acquired from 
NOF Corporation (White Plains, NY). 2,4,6-Trinitrobenzene Sulfonic Acid (TNBS) assay 
was purchased from Thermo Scientific (Waltham, MA). DJ-1 Stealth siRNA and Vybrant 
Dye Cycle Green were purchased from Life Technologies (Grand Island, NY). siGLO Red 
Transfection Indicator was obtained from GE Dharmacon (Lafayette, CO). Roswell Park 
Memorial Institute (RPMI) media and Dulbecco’s Phosphate Buffered Saline (DPBS) were 
acquired from Mediatech (Manassas, VA). Calcein AM cell viability assay and GSH-Glo 
assay kits were purchased from Enzo Life Sciences (Farmingdale, NY). 10% pre-cast Tris-
Glycine acrylamide gels and Trans-Blot Turbo packs were obtained from Bio-Rad 
(Hercules, CA). Peroxy Yellow 1 (PY1) was purchased from Sigma-Aldrich (St. Louis, 
MO). All other chemicals and supplies were obtained through VWR International (Radnor, 
PA).
Methods
Synthesis and characterization of the nanoplatform for siRNA delivery—PPIG4 
dendrimer-based nanoplatform loaded with siRNA (siRNA-NP) was constructed according 
to the previously described procedure.21–23 Synthesis of the siRNA-NP was initiated by 
mixing DJ-1 siRNA (10 μM) with the PPIG4 at a nitrogen to phosphate (N/P) ratio of 4 in 
MilliQ water and vortexing the reaction mixture for 1 h at room temperature. Afterwards, 
MAL-PEG-NHS was added to the reaction mixture (NHS : NH2 = 1 : 5 molar ratio) and the 
solution was vortexed during 1 h at room temperature. Finally, the LHRH peptide was 
introduced to the solution (MAL-PEG-NHS : LHRH = 1 : 5 molar ratio) and the reaction 
mixture was incubated for 12 h at room temperature. The complexation efficiency of siRNA 
with PPIG4 was validated via gel retardation assay as previously described.22–26 Surface 
modification of siRNA-PPIG4 complexes with PEG and LHRH peptide was confirmed by 
using TNBS and the bicinchoninic acid assay (BCA) assays according to the previously 
reported procedures.23, 27 The hydrodynamic diameter and zeta potential of the developed 
nanoplatform were evaluated by employing dynamic light scattering (Malvern ZetaSizer 
NanoSeries, Malvern, U.K.) as previously described.28
Cell Culture—A2780/CDDP, ES2, IGROV1, SKOV3 human ovarian carcinoma cells were 
cultured using RPMI culture media supplemented with 10% FBS and 1% streptomycin/
ampicillin. Cells were grown at 37 °C in a humidified atmosphere of 5% CO2 (v/v) in 
air.28–30
Cellular internalization of the siRNA-NP—Flow cytometry was employed to evaluate 
cellular internalization efficiency of the siRNA-NP.27, 29 Briefly all cells were seeded in a 
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six well cell culture plate at a density of 3 × 105 cells per well in RPMI media and allowed 
to adhere to the plate overnight. Then, the prepared nanoplatform loaded with Dy-547 
labeled siRNA, was added to the cells (siRNA = 1 μM) and incubated for 24 h prior to flow 
cytometry analysis. The cells were trypsinized, collected in 0.5 mL Eppendorf tubes, washed 
3 times with DPBS, resuspended in 200 μL DPBS, and analyzed using an Accuri C6 flow 
cytometer (BD Biosciences, San Jose, CA). All data analyses were performed using the BD 
C6 Accuri software. For the quantification of siRNA internalization via flow cytometry no 
gating was used. Before the cellular uptake analysis non-treated cells were evaluated and the 
auto fluorescence was measured and recorded to be in the 103 fluorescence decade for all the 
tested cell lines. Then the cells treated with the constructed nanoplatform were analyzed and 
histograms were plotted. To determine the percentage of cells transfected with the dye-
labeled siRNA we drew a line using the BD software at the 103 decade and then allowed the 
software to calculate percent cells containing fluorescently labeled siRNA.
Calcein AM Cell Viability Assay—For all cell viability endpoint experiments a modified 
Calcein AM assay was performed by following our previously published 
protocol.21, 27, 29–31
Real Time Quantitative PCR (qPCR) analysis—qPCR was used to validate gene 
expression in each cell model before and after treatment with the siRNA-NP (siRNA = 1 
μM) for 24 h.21, 22 Briefly, total RNA was extracted from the treated cells using an RNeasy 
extraction kit (Qiagen, Hilden, Germany) and RNA concentrations were determined using a 
BioSpec-nano UV-Vis Spectrophotometer (Shimadzu, Columbia, MD). Reverse 
transcription was carried out using High-Capacity cDNA Reverse Transcription Kit (Thermo 
Scientific) according to manufacturer’s protocol. Following cDNA preparation 100 ng of 
each sample was loaded into the 96 well qPCR plate at a final volume of 20 μL, using β-
actin as endogenous control. Taqman primers for all gene targets were used for cDNA 
template amplification. The qPCR plate was read using a Applied Biosystems Step One Plus 
qPCR system (Thermo Scientific) with an initial cycle step at 50°C for 2 min followed by 40 
cycles of 95°C for 15 s then 60°C for 1 min. The Ct threshold values were automatically 
determined by the software, and all samples were done in triplicate for statistical analysis.
Western Immunoblotting analysis—Western immunoblotting analysis was performed 
to confirm intracellular protein levels in all studied cell lines before and after treatment with 
the siRNA-NP.21 Briefly all cell lines were seeded in T-25 flask at a cell density of 20 × 105 
and incubated overnight at 37°C. Afterward the media was removed and 3.6 mL of fresh 
media along with 0.4 mL of DJ-1 siRNA-NP was added to each flask (total volume 4 mL; 
final siRNA concentration = 1 μM). The cells were collected and analyzed at various time 
points. The immunoblotting procedure was carried out via our previously published 
protocol.21 The antibodies were purchased from Thermo Scientific (Waltham, MA) and 
antibody dilutions used in each experiment are as follows: DJ-1 (1:1000), NRF2 (1μg/mL), 
p53 (1:500), phosphoAkt (1μg/mL), and β-actin (1:5000). The western blot band 
quantification analysis was performed using ImageJ software. Band intensities of the tested 
proteins are expressed as the percentage of the β-actin band intensity, which was set to 
100%.
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ROS and GSH measurements—PY-1 and Glo-GSH Glutathione (Promega, Madison, 
WI) kit-based assays were employed to evaluate intracellular levels of hydrogen peroxide 
(H2O2) and GSH respectively in all cell lines prior to and after treatment with the siRNA-
NP. The PY-1 assay was performed as per our previously published procedure.21 For GSH 
measurements, all cells were seeded at a density of 5 × 103 in a clear bottom opaque walled 
96 well plate to increase signal intensity. Then the cells were treated with the siRNA-NP 
(1μM) for 24 h, followed by the assaying procedure according to the manufacture protocol. 
The luminescence was read and analyzed using a Biotek synergy HT plate reader and 
software (Biotek, Winooski, VT).
Real time cellular proliferation study—Cellular proliferation was measured using the 
xCELLigence real time proliferation platform (ACEA Biosciences, San Diego, CA).21 Prior 
to the assay, the E-plates were coated with 50 μL of fibronectin (10μg/mL) (Sigma-Aldrich), 
per manufacturer’s protocol, and left in the biosafety cabinet for 30 min. Subsequently, the 
plates were aspirated and 100 μL of cell free media was added to each well, followed by a 
30 min equilibration period in the bio safety cabinet. The plates were then loaded onto the 
instrument and background measurements were recorded for each of them using the RTCA 
Software 1.2. Next, cells were seeded in each plate at a cellular that it resulted in growth that 
did not reach 100% confluency in a 96 h time period density (A2780/CDDP: 5,000 cells/
well; ES2: 2,500 cells/well; IGROV1: 5,000 cells/well) and placed back into the incubator to 
adhere to the plate before analysis. Once the cells adhered to the plate, they were placed onto 
the proliferation platform and the experiment was started. After 2 h, 10 μL of media was 
removed from the wells assigned for DJ-1 siRNA treatment alone and combinatorial therapy. 
Ten μL of 10 μM DJ-1 siRNA-NP solution were added to the remaining 90 μL of media in 
each well, resulting in a total volume of 100 μL and a final DJ-1 siRNA concentration of 1 
μM. Following a 24 h incubation period with the DJ-1 siRNA-NP, an additional 90 μL of 
media was added to the wells assigned for CDDP treatment only and combinatorial therapy. 
Then, 10 μL of the corresponding concentrations of CDDP was added to these wells to 
achieve the required IC50 concentrations for each cell line (A780/CDDP = 23.6 μM, ES2 = 
3.8 μM, and IGROV = 1.9 μM). The IC50 concentrations for each cell line were determined 
by using xCELLigence real time proliferation platform in time dependent manner (Figure 
S1). In case of the control and DJ-1 siRNA therapy only, 100 μL of media was added to the 
corresponding wells. The plates were then monitored for 96 h and analyzed using RTCA 
Software 1.2.
Migration Assay—Cell migration was evaluated using a modified wound healing assay.32 
Briefly, A2780/CDDP, ES2, and IGROV1 cells were seeded in a 6-well plate at a density of 
2.5 × 105 cells per well and allowed to reach ~85% confluency before treatment. Afterwards 
the scratch was made in a cell monolayer using a 200μL pipette tip. Immediately after the 
scratching, the cells were washed with DPBS to remove any cellular debris, followed by 
addition of fresh media containing the nanoplatform loaded with DJ-1 siRNA (final 
concentration 1μM) to the respective wells. After 24 h, CDDP was added to the 
corresponding wells assigned for CDDP alone and combinatorial therapies at the following 
concentrations (A780/CDDP = 23.6 μM, ES2 = 3.8 μM, and IGROV = 1.9 μM). Images of 
the cells were taken at 0, 24, and 48 h after a scratch was made to monitor cellular 
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movement and gap reduction. Wound widths after 0 and 48 h were measured and % wound 
closure was calculated as follows:
where W0h and W48h are the wound widths before and 48 h after treatment.
Cell cycle analysis—All cell lines were seeded in 6 well cell culture plates at a density of 
3 × 105 cells per well and allowed to incubate at 37°C in 5% CO2 overnight. The following 
day the media was removed and 1.8 mL of media along with 0.2 mL of 10 μM DJ-1 siRNA 
loaded in the nanoplatform was added to the wells assigned for DJ-1 siRNA only and 
combinatorial therapies, followed by an incubation period of 24 h. After 24 h CDDP was 
added to the wells assigned for CDDP and combinatorial treatments and incubated for 
another 24 h. The next day the cells were trypsinized, collected in 1.5 mL Eppendorf tubes, 
and washed 3 times with DPBS. After washing the cells Vybrant Dye Cycle Green was 
added to each tube according to the manufacturer’s protocol and incubated for 2 h at 37°C in 
5% CO2 before flow cytometry analysis. All data was analyzed using BD C6 Accuri 
software.
Caspase assay—The caspase assay (Thermo Fisher, Brookfield, WI) was performed to 
quantify caspase activity in the used cell lines after each treatment. All cell lines were 
seeded at a density of 5 × 103 cells per well in a black opaque walled clear bottom 96 well 
plate (Corning, Corning, NY) and incubated overnight at 37°C and 5% CO2. The following 
day cells were treated with CDDP, siRNA-NP and combinatorial therapy as described above. 
After treatment, cells were then labeled with 7.5 μM CellEvent™ Caspase-3/7 Green 
Detection Reagent for 30 minutes at 37°C and fluorescence was measured using a multi-well 
plate reader (Synergy HT, BioTek Instruments, Winooski, VT) with 485 nm excitation and 
528 nm emission filters. Cells were also imaged with an EVOS FL Cell Imaging System 
(Life Technologies, Grand Island, NY).
Statistical analysis—Data was analyzed using descriptive statistics, single-factor analysis 
of variance (ANOVA), and presented as mean values ± standard deviation (SD) from three to 
six independent measurements. The comparison among groups was performed by the 
independent sample Student’s t test. The difference between variants was considered 
significant at p < 0.05.
RESULTS AND DISCUSSION
Selection and Characterization of Ovarian Cancer Models
To evaluate the therapeutic effect of DJ-1 protein suppression alone or in combination with 
CDDP for ovarian cancer treatment, three characteristically different human ovarian 
carcinoma cell lines such as A2780/CDDP, ES2 and IGROV-1 of various origins, 
phenotypes, growths rates and CDDP resistance levels were employed. The A2780/CDDP 
human epithelial ovarian cancer cell line (doubling time = 25 h) is highly resistant to the 
CDDP.33 On the contrary, the ES2 human clear cell adenocarcinoma cell line (doubling time 
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= 19 h) exhibits low to moderate resistance to a number of chemotherapeutic drugs including 
CDDP.33 Finally, the IGROV1 human ovarian carcinoma cell line of the mixed origin 
(doubling time = 27 h) is sensitive to CDDP.33, 34 To experimentally confirm the indicated 
resistibility of the employed cancer cell lines to the CDDP, their real time proliferation 
profiles, after incubation with various concentrations of the drug, were measured and the 
IC50 values of 23.6 μM, 3.8 μM and 1.9 μM were obtained for A2780/CDDP, ES2 and 
IGROV-1, respectively (Figure S1). According to qPCR and immunoblot analyses, all tested 
ovarian cancer cell lines overexpress DJ-1 when compared to non-malignant HUVEC cells 
(Figure 3A). The selection and use of HUVEC cells as a control was determined on the basis 
that HUVEC cells are a non-cancerous cell line and they are of epithelial origin as well as 
the tested ovarian cancer cells. HUVEC cells were employed as an intracellular base line of 
the metabolic activities of a normally functioning cell. Moreover, the platinum-resistant 
A2780/CDDP cells exhibited 1.8- and 2.4-fold increase in the basal level of DJ-1 mRNA as 
compared to the platinum-sensitive ES2 and IGROV cells, respectively (Figure 3A). The 
obtained results are in a good agreement with previous reports indicating that higher 
expression levels of DJ-1 increase the chemoresistance of cancer cells by inhibiting various 
apoptotic pathways.9, 18 For example, the proteomic studies performed by Zeng et al. 
demonstrated that CDDP resistant lung cancer cells exhibited a 5.4-fold increase in basal 
level of DJ-1 relative to their drug-sensitive counterparts.12
Preparation and Characterization of the Nanoplatform for DJ-1 siRNA Delivery to the 
Ovarian Cancer Cells
siRNA delivery to the cancer cells is significantly hindered by a number of factors including 
its nuclease degradation in serum and electrostatic repulsion by the negatively charged 
cellular membrane.35 To facilitate intracellular siRNA delivery and achieve the efficient 
suppression of DJ-1 mRNA, we constructed a dendrimer-based nanoplatform targeting the 
ovarian cancer cells (Figure 2). Due to a high positively charged surface, the amine-
terminated PPIG4 dendrimers were able to effectively complex negatively charged siRNA 
molecules through electrostatic interactions (Figure 3B).21, 22, 26 To minimize toxicity and 
enhance biocompatibility, the positively-charged PPIG4-siRNA complexes (ζ = +23.03 
± 2.22 mV) were modified with heterobifunctional PEG molecules by coupling NHS ester 
groups of PEG to the primary amino groups of the dendrimers (Figure 2).21, 23, 29, 30 As a 
result of this modification, the average zeta potential value of the PPIG4-siRNA complexes 
decreased from +23.03 ± 2.22 mV to + 6.44 ± 2.14 mV indicating that the majority of 
primary amine groups, which could cause cellular membrane damage, were successfully 
PEGylated. The toxicity study validated that in comparison to non-modified PPIG4 
complexes loaded with scrambled siRNA, the PEGylate complexes do not compromise 
cellular viability (Figure 3C). Finally, to improve nanoplatform specificity to the ovarian 
cancer cells, degradation-resistant LHRH peptide was attached to the distal end of PEG, by 
coupling the maleimide group of PEG to cysteine thiol presented in the LHRH sequence 
(Figure 2).21–23 The employed targeting moiety exploits preferential overexpression of 
LHRH receptors on the extracellular surface of the various ovarian cancer cells, including 
A2780/CDDP, ES2 and IGOV-1 cells.20–23, 36–41 Recently, we reported that gynecologic 
(both primary and metastatic) tumors, obtained from patients with advanced ovarian 
carcinoma, overexpressed LHRH receptors.42 Conversely, in the majority of healthy organs, 
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there were no detectable levels of LHRH receptors.42 Moreover, our previous reports 
confirmed that nanoplatforms equipped with LHRH peptide can efficiently deliver siRNA 
molecules to LHRH-positive cancer cells both in vitro and in vivo.21–25 Following the 
modification steps, we determined hydrodynamic size of the constructed siRNA 
nanoplatform, which turned out to be 147.8 ± 11.0 nm (Figure 3D). The LHRH-targeted, 
nanoplatform loaded with the scrambled siRNA, did not compromise viability (Figure 3C), 
proliferation (Figure S2) and DJ-1 mRNA expression (Figure S3) of ovarian cancer cells, 
indicating that the prepared siRNA delivery system is non-toxic.
To assess the cellular internalization efficiency of the LHRH-equipped nanoplatform and 
investigate the role of LHRH peptide as a targeting ligand, LHRH receptor-positive (A2780/
CDDP, ES2 and IGROV1)39–41 and LHRH receptor-negative (SKOV3)39 ovarian cancer cell 
lines were incubated with the delivery system containing fluorescently labeled siRNA for 24 
h. According to the flow cytometry measurements, fluorescence signal was detected in more 
than 85% A2780/CDDP, ES2 and IGROV1 cells, thus reflecting high internalization 
efficiency of the nanoplatform into the LHRH receptor-positive ovarian cancer cell lines 
(Figure 4). In contrast, only 50% LHRH receptor-negative SKOV3 cells were transfected 
with the LHRH-targeted nanoplatform (Figure S4), indicating preferential uptake of the 
constructed nanoplatform by the LHRH-positive cancer cells.
The qPCR analysis revealed that the 1μM DJ-1 siRNA delivered by the prepared 
nanoplatform downregulated the expression of targeted mRNA to 22%, 15% and 14% of the 
basal level in A2780/CDDP, ES2 and IGROV1 cells at 24 h post-transfection, respectively 
(Figure 5A). In case of ES2 and IGROV1 cells, the suppression of DJ-1 mRNA levels 
persisted 96 h following a single transfection. In contrast, the intracellular level of DJ-1 
mRNA in the CDDP-resistant A2780 cells was gradually restored under the same 
experimental conditions, recovering from the 22% after 24 h to 90% of the basal level at 96 
h. This finding indicates that A2780/CDDP cells rely on DJ-1 protein for continued growth 
and CDDP chemoresistance. The western immunoblotting analysis further confirmed the 
similar trend in DJ-1 protein expression at the studied time points (Figure 5B). The 
suppression of DJ-1 protein in both ES2 and IGROV1 cells remained persistent (<5% of the 
basal level) at 96 h after a single transfection. Contrary to the qPCR data, the western blot 
analysis revealed that the steady-state protein levels of DJ-1 in A2780/CDDP cells 24 h after 
DJ-1 suppression were decreased to 11% of the basal DJ-1 protein concentrations, and after 
96 h only recovered to 54%, indicating that the intracellular amount of DJ-1 protein 
remained substantially suppressed at this time point. The discrepancy between mRNA and 
protein levels is due to the finite amount of time between mRNA production and functional 
protein assembly.
To achieve an efficient silencing of DJ-1 mRNA and the corresponding protein, 1 μM siRNA 
therapeutic dose has been chosen based on the experimental observation. The qPCR data 
revealed a dose dependent suppression of DJ-1 mRNA in the ovarian cancer cells 24 h after 
transfection with the constructed nanoplatform containing various siRNA concentrations and 
only 1 μM siRNA resulted in greater than 85% mRNA silencing (Figure S5). The selected 
relatively high dose of DJ-1 siRNA is in a good agreement with a previously published 
report, which indicated that complete suppression of DJ-1 mRNA was only achieved after 
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cells incubation for 36 h with 2 μM siRNA encapsulated in the commercially available 
Oligofectamine.43 Our in vivo experiments further confirmed that DJ-1 siRNA (1.1 mg/kg) 
delivered by the constructed nanoplatform after intravenous injection into mice bearing 
subcutaneous ovarian cancer xenograft can substantially suppress the targeted DJ-1 protein 
in cancer tissue (Figure S6). The employed siRNA dosage is in good agreement with the 
previous clinical trials, which validated that administration of 1.5 mg/kg formulated siRNA 
was well tolerated and has antitumor activity.44
Effect of DJ-1 Protein Suppression on Cancer Cells Proliferation, Viability and Migration
By measuring cell growth in real time with the xCELLigence System, it was demonstrated 
that suppression of DJ-1 protein expression with siRNA, delivered by the constructed 
nanoplatform, dramatically impaired proliferation of the employed ovarian cancer cells as 
compared to the controls (Figure 6). It is worth mentioning that knockdown of DJ-1 
expression by siRNA produced a superior reduction in ovarian cancer cell proliferation than 
CDDP alone at the corresponding IC50 concentrations (Figure 6). Finally, the combinatorial 
therapeutic approach led to the most pronounced inhibition of proliferation in all the studied 
cell lines, outperforming both siRNA-mediated DJ-1 knockdown and CDDP treatment alone 
(Figure 6). A decrease in cellular proliferation can be initially seen at ~48 h after the 
addition of siRNA to the culture media in all cell lines. The observed effect is consistent 
with the qPCR and western blot data (Figure 5), which validate the substantial suppression 
of both DJ-1 mRNA and protein levels at the ~48 h time point. Furthermore, the inhibitory 
effect of DJ-1 suppression on cell proliferation was most pronounced at 72 and 96 h post-
treatment, where DJ-1 is predicted to have 3–4 half-lives of turn over, 45 achieving maximal 
intracellular suppression.
In addition to the real-time proliferation studies, we also evaluated the effect of DJ-1 
suppression alone or in combination with CDDP on the viability of cancer cells using 
Calcein AM assay at 72 and 96 h post-transfection. As shown in Figure 7, siRNA-mediated 
silencing of DJ-1 protein reduced viability of all the studied ovarian cancer cell lines. It is 
noteworthy that the decrease in viability was the most pronounced in the CDDP-resistant 
ovarian cancer cells (A2780/CDDP), which are characterized by the highest overexpression 
of the DJ-1 protein (Figure 3A). In contrast, non-resistant IGROV cells, which exhibit the 
lowest DJ-1 protein expression (Figure 3A), were found to be the least sensitive to the 
siRNA treatment. Thus, viability of A2780/CDDP cells decreased from 100% to 32.3% 96 h 
post-transfection relative to the control (Figure 7). In contrast, the viability of ES-2 ovarian 
cancer cells with low resistance to CDDP and non-resistant IGROV-1 cells was 52.0 and 
77.4% following the same treatment, respectively (Figure 7). Combination of DJ-1 siRNA 
and CDDP lead to further decrease in cellular viability down to 14.3, 16.3 and 24.2% for 
A2780/CDDP, ES-2, and IGROV-1 respectively. These results revealed that higher cellular 
levels of DJ-1 could increase the survival of the ovarian cancer cells and enhance their 
resistance to platinum-based chemotherapeutic drugs. Therefore, the siRNA-mediated 
silencing of DJ-1 can efficiently inhibit both cancer cell survival and proliferation all the 
while improving their sensitivity to chemotherapy. The obtained data is consistent with the 
previous reports, which demonstrated that DJ-1 protein suppression in cancer cells can 
effectively enhance the efficacy of the anti-cancer therapies.21, 46 For example, Zhang et al. 
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reported that the sensitivity of adriamycin resistance MCF-7 breast cancer cells to 
chemotherapy was significantly improved following DJ-1 knockdown. In another study, 
Schumann et al. demonstrated that the therapeutic efficacy of the photodynamic therapy for 
ovarian cancer treatment was substantially enhanced through the siRNA-mediated inhibition 
of the DJ-1 protein and this effect was more pronounced in A2780/AD cells than in ES2 
cells, wherein former cells are characterized by higher basal levels of DJ-1 protein.21
Because intracellular DJ-1 is known to regulate the process of cancer cell migration,47, 48 we 
also employed the wound healing assay to assess an effect of siRNA-mediated DJ-1 
knockdown alone or in combination with CDDP on the migration capacity of ovarian cancer 
cells. Immediately after initiating an appropriate treatment, a scratch was made in the cell 
monolayer and migration of cancer cells to the wound area was monitored at different time 
points. In comparison to non-treated cells, cancer cells exposed to CDDP alone 
demonstrated some decrease in migration (Figure 8). Furthermore, both DJ-1 suppression 
alone and combinatorial therapy inhibited ovarian cancer cell motility. The obtained results 
indicated that not only siRNA-induced DJ-1 suppression in combination with CDDP is 
capable of a substantial reduction in ovarian cancer cell proliferation and viability, but it also 
can suppress their migration and thus inhibit the potential metastasis development. These 
results are in a good agreement with the previous studies reported by He et al., which 
indicated that the cellular levels of DJ-1 correlate with migration and invasion of pancreatic 
ductal adenocarcinoma cells and knockdown of DJ-1 expression can inhibit metastasis in 
vivo.47 In another study, Pei et al. also reported that high expression of DJ-1 in 
nasopharyngeal carcinoma enhances migratory properties of cancer cells in vitro and plays a 
significant role in lymph node metastasis.48 Finally, Feng et al. reported that overexpression 
of DJ-1 promotes migration of human glioma cells possibly through DJ-1-induced down 
regulation of phosphatase PTEN.49
Role of the DJ-1 Protein Suppression in the Combinatorial Therapeutic Approach
The observed superior anticancer effect of the combinatorial treatment is related to the fact 
that the employed individual therapies can target multiple pathways that drive ovarian cancer 
progression. It is established that CDDP halts the growth of ovarian carcinomas primarily 
through the induction of DNA crosslinks and inhibition of cellular division.50 Unlike CDDP, 
the siRNA-mediated DJ-1 silencing can concurrently affect several pathways that ovarian 
cancer cells use for their proliferation, survival, migration and resistance to the 
chemotherapeutic agents (Figure 1). We sought to interrogate molecular underpinnings of 
the DJ-1 knockdown effects in the treatment of the ovarian cancer cells. Firstly, DJ-1 protein 
plays a vital role in the proliferation and growth of cancer cells through direct mediation of 
the Akt pathway.14, 51 It binds to PTEN thereby decreasing PTEN activity and increasing 
phosphorylation of protein kinase Akt, thus promoting unregulated proliferation of cancer 
cells (Figure 1A).9 Consequently, an increase in DJ-1 basal levels is associated with 
enhanced aggressiveness of the cancer. For example, Wang et al. revealed that the 
overexpression of DJ-1 in laryngeal squamous carcinoma cells is correlated with increased 
expression of phosphorylated Akt (p-Akt) and the high intracellular levels of DJ-1 can 
accelerate proliferation rate, increase the invasiveness and migration capacity, and reduce 
apoptosis, by activating the PI3K/Akt/mTOR signaling axis.52 It has been confirmed that the 
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proliferation rate of DJ-1-overexpressing SNU-46-D1 cells was faster than normal SNU-46 
cells. Through the modulation of this signaling axis DJ-1 has also been implicated in tumor 
growth and progression by upregulating hypoxia-inducible factor-1 (HIF1) protecting the 
cells against hypoxia induced apoptosis. Vasseur et. al. reported a link between DJ-1 and 
Akt, mTOR, and HIF1 activation as well as inhibition of p53-mediated cellular apoptosis in 
tumor progression.53 In our study, immunoblot analysis validated that suppression of DJ-1 
protein expression with siRNA delivered by the prepared nanoplatform, caused substantial 
decrease in p-Akt levels in all the ovarian cancer cell lines tested (Figure 9A). Consequently, 
the proliferation and viability of these cells was significantly decreased (Figures 6 and 7). 
By analyzing perfusions and solid ovarian cancer tumors, Davidson et al. validated that DJ-1 
is commonly expressed in advanced-stage ovarian carcinoma, but PTEN expression is 
infrequent. It is assumed that DJ-1 expression could have a prognostic role in ovarian 
carcinoma, possibly by suppressing the inhibitory action of PTEN on the Akt survival 
pathway.10
Second, DJ-1 could promote cancer cells survival, growth, and contributes, in part, to CDDP 
resistance by repressing activity of p53 tumor suppressor protein.15, 54 The cytoprotective 
function of DJ-1 is related to its ability to sequester p53, therefore inhibiting the apoptotic 
p53-Bax-caspase pathway and cell cycle arrest functionality (Figure 1B).1555 The 
aforementioned Akt signaling pathway is also influenced by the p53 protein activity. 
Astanehe et al. reported that p53 binds to the promoter of PI3K and inhibits its actions, 
preventing the phosphylation of Akt, thereby decreasing cell proliferation and growth.56 
Using western blot analysis, we assessed a change of p53 protein level in the ovarian cancer 
cells before and after treatment with the nanoplatform containing DJ-1 targeted siRNA. A 
substantial increase in p53 protein expression was found in the all tested cancer cells 
following siRNA treatment indicating inverse correlation between DJ-1 protein levels and 
p53 expression (Figure 9B). To further validate the role of DJ-1 suppression in regaining p53 
function and the subsequent negative impact on cells proliferation and viability, we assessed 
caspase activity and cell cycle parameters of the cells in question before and after treatment 
with DJ-1 siRNA-NP, CDDP or combinatorial therapy. The siRNA-mediated attenuation of 
DJ-1 and the consequent increase in p53 expression resulted in blockade of cell cycle 
progression at the G0/G1 phase (Figure 10). When compared to the untreated cells, the 
G0/G1 population of siRNA-treated A2780/AD, ES2 and IGROV-1 cells increased by 43.6, 
33.9, and 29.4%, respectively (Figure 10). This result suggests that the A2780/CDDP 
ovarian cancer cells with the highest basal level of DJ-1 protein are most susceptible to the 
DJ-1 siRNA-induced cell cycle arrest. Importantly, this susceptibility declines with 
decreasing basal levels of DJ-1 as seen in ES2 and IGROV-1 cell lines. Finally, the 
combinatorial therapy showed the most pronounced effect in blocking cell cycle progression 
as compared to the standalone DJ-1 siRNA and CDDP treatments. The number of 
A2780/AD, ES2 and IGROV-1 cells in the G0/G1 phase following combinatorial therapy 
increased by 52.4, 40.6, and 37.4%, respectively when compared to the untreated cells. To 
the best of our knowledge, this is the first report demonstrating that the knockdown of DJ-1 
protein in ovarian cancer cells results in cell cycle arrest at the G0/G1 phase, which likely 
contributes to the decrease in cell proliferation and viability. Previous studies showed that 
certain anticancer agents such as curcumin and ellagic acid induced G0/G1 cell arrest 
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through increased p53 levels and caused apoptosis in human bladder and breast cancer 
cells.57, 58
By using caspase assay, we also demonstrated that siRNA-mediated knockdown of DJ-1 
protein substantially increased caspase activation in all the tested ovarian cancer cell lines in 
comparison to the control and CDDP treatment alone (Figure 11A and S7). Our results are 
in good agreement with the previous report, which indicated that DJ-1 blocks caspase-3 
activation by repressing p53 function and therefore, decreasing the Bax protein level.15 It is 
important to mention that the detected effect was the most pronounced in A2780/CDDP 
cells characterized by the highest intracellular level of the DJ-1 protein. Thus, in comparison 
to non-treated cells, incubation of A2780/CDDP, ES2 and IGROV1 cells with siRNA-NP 
increased caspase activity by 75.6, 51.1, and 38.3%, respectively (Figure 11A). Finally, 
combinatorial treatment resulted in further increase of caspase activation by 106.4, 84.9 and 
83.6% in A2780/CDDP, ES2 and IGROV1 cells, respectively. The above results provided 
evidence that siRNA-mediated DJ-1 silencing in ovarian cancer cells inhibits DJ-1 protective 
function associated with its ability of repressing p53 transcriptional activity, therefore 
inhibiting the apoptotic p53-Bax-caspase pathway and cell cycle arrest functionality.
One of the main alterations in ovarian cancer cells, compared to nonmalignant ones, is 
excessive cellular levels of toxic reactive oxygen species (ROS).59 The cancer cells have 
developed a ROS defense system to protect themselves from intrinsic oxidative stress and to 
provide resistance to ROS-induced therapies.60 Through multiple mechanisms, DJ-1 protein 
plays an important role in protecting ovarian cancer cells from toxic intracellular ROS and 
the exogenous ROS generated by various anticancer agents, including CDDP.61 Therefore, 
weakening the cellular ROS defense mechanism by siRNA-mediated DJ-1 knockdown may 
result in ROS-mediated cell death.
DJ-1 has been shown to influence synthesis of the non-enzymatic antioxidant, reduced 
glutathione (GSH), via upregulation of the rate limiting enzyme glutamate cysteine ligase 
(GCL) thereby increasing intracellular GSH pool (Figure 1C).17 Godwin et al. reported that 
ovarian cancer cells with a platinum resistant phenotype have increased intracellular GSH 
concentration with a linear relationship to resistance.62 We also verified that platinum-
resistant A2780/CDDP cells have the highest basal levels of GSH when compared to the 
ES2 and IGROV1 cells lines (Figure 11B). Following DJ-1 suppression, intracellular GSH 
level is decreased by 56.4% in the A2780/CDDP cells where the ES2 and IGROV1 cells 
were characterized by a 31.6% and 21.7% reduction, respectively (Figure 11B). These data 
are in good agreement with the published hypothesis that GSH upregulation in platinum-
resistant cancer cells and the reliance of these cells on DJ-1 as a cellular GSH 
mediator. 17, 62
Additionally, DJ-1 has been reported to directly influence the activity of the oxidative stress-
responsive transcription factor NRF2, stabilizing it, therefore inhibiting its association with 
the ubiquitinase Keap1 and increasing NRF2’s transcriptional activity.63–65 NRF2 plays a 
critical role in redox regulation within the cell and is responsible for NRF2-regulated GSH 
recycling via modulating the activity of glutathione reductase as well as transcriptional 
regulation of a variety of other antioxidant stress response proteins (Figure 1C).16, 66, 67 
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Using western blot analysis, we assessed NRF2 protein levels following siRNA-mediated 
DJ-1 suppression and found a significant decrease in the amount of NRF2 protein in all the 
tested cell lines, thus confirming DJ-1’s role in NRF2 stabilization (Figure 11C). Clements 
et al. previously revealed that in the absence of intact DJ-1, NRF2 protein is unstable, and 
transcriptional responses are consequentially decreased - both basally and after induction.63 
Hence, the DJ-1/NRF2 functional axis presents a prospective therapeutic target in cancer 
treatment and DJ-1 knockdown could contribute to ROS-mediated cell death.
Finally, it has been reported that the redox-sensitive Cys-106 residue of DJ-1 is highly 
susceptible to hydrogen peroxide (H2O2)-induced oxidation and may be responsible for 
H2O2 scavenging.68 Consistently, DJ-1 has been shown to reduce or prevent H2O2-mediated 
cell death.43 To evaluate the effect of DJ-1 suppression and CDDP on intracellular H2O2 
levels, the employed cancer cell lines were subjected to the siRNA-loaded nanoplatform, 
CDDP or combinatorial treatment. Following DJ-1 suppression, we observed an 81.0% 
increase in intracellular H2O2 in the platinum resistant A2780/CDDP cells and a 63.4% and 
46.2% increase in ES2 and IGROV1 cells, respectively (Figure 11D). This data is in 
agreement with the basal levels of DJ-1 reported in this study, whereby higher levels of DJ-1 
in the cells permit a more robust and efficient ROS scavenging.
Similarly, CDDP has been shown to stimulate the production of endogenous ROS.69 To 
understand the impact of CDDP on enhanced intracellular ROS generation, all cell lines in 
question were treated at their respective IC50 concentrations. Following the treatment, these 
cell lines exhibited small increase in ROS, ranging from a 2.02 to 12.32% relative to control 
(Figure 11D). 69, 70 The elevated ROS seen with CDDP+DJ-1 suppression regimen was 
greater than the increase in ROS seen in the sole DJ-1 suppression treatment group. Out of 
all the cell lines the most pronounced ROS elevation occurred in the A2780/CDDP cell line, 
where the difference between the DJ-1 suppression only and the combinatorial treatment 
was 28.83% versus 11.36% and 8.45%, seen in the ES2, and IGROV-1 cell lines, 
respectively (Figure 11D).
The above results revealed that upon DJ-1 suppression there is a reproducible substantial 
increase in endogenous H2O2 as well as a significant decrease of intracellular GSH pool and 
NRF2 protein. Such alteration in the intercellular ROS (produced as a consequence of a 
weakened antioxidant defense system) further confirms the reliance of ovarian cancer cells 
on DJ-1, which acts as a buffer for intracellular ROS. This data is in agreement with our 
previously published observation of a dramatic increase in endogenous ROS in the DJ-1-
overexpressing A2780/AD (Adriamycin-resistant) cells upon the protein’s depletion in 
combination with ROS-inducing photodynamic therapy.21
CONCLUSIONS
A dendrimer-based, LHRH-targeted drug delivery system was constructed to deliver DJ-1 
targeted siRNA to ovarian cancer cells in combination with CDDP. The DJ-1 nanoplatform 
showed sufficient cellular uptake to achieve therapeutic DJ-1 mRNA suppression levels. The 
silencing of DJ-1 provided a therapeutic approach that encompassed three ovarian cancer 
survival pathways that intersect with CDDP’s mechanism of action: (i) increasing apoptosis; 
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(ii) decreasing cellular proliferation; and (iii) increasing intracellular ROS levels. In this 
study, we found that DJ-1 suppression in combination with CDDP treatment is a feasible 
therapeutic modality, and offers a new prospective avenue for the treatment of CDDP- 
resistant ovarian cancer. The current work established a foundation for subsequent 
evaluation of the developed combinatorial therapy in animal models with either 
subcutaneous or orthotopic ovarian cancer tumors.
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Figure 1. 
Schematic illustration of the dendrimer-based nanoplatform for targeted delivery of DJ-1 
siRNA to the ovarian cancer cells via LHRH receptor-mediated endocytosis and the role of 
siRNA-induced suppression of DJ-1 protein in the combinatorial treatment. siRNA-mediated 
knockdown prevents DJ-1 protein from (A) inhibiting the PTEN expression, thereby 
promoting phosphorylation of Akt and activating cell proliferation and migration; (B) 
suppressing p53 transcriptional activity, therefore inhibiting the apoptotic p53-Bax-caspase 
pathway and cell cycle arrest functionality; (C) protecting cancer cells from intrinsic 
oxidative stress and the consequent ROS-mediated apoptosis. DJ-1 facilitates GSH synthesis 
via upregulation of the rate-limiting enzyme glutamate cysteine ligase (GCL). In addition, 
DJ-1 stabilizes NRF2, which is responsible for both GSH recycling via modulating the 
activity of glutathione reductase (GR) and transcriptional activation of various antioxidant 
proteins.
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Figure 2. 
Schematic representation of the LHRH-targeted, PPIG4 dendrimer-based nanoplatform for 
siRNA delivery. The developed nanoparticles contain four components: 1) DJ-1 siRNA, as 
suppressors of the corresponding mRNA in the ovarian cancer cells; 2) PPIG4 dendrimers as 
carriers for DJ-1 siRNA; 3) PEG, as an enhancer of nanoparticles stability and 
biocompatibility and 4) LHRH peptide, as a targeting moiety to the ovarian cancer cells. The 
approach for preparation of the nanoplatform consists of the following steps: 1) 
Complexation of negatively charged DJ-1 siRNA by the positively charged PPIG4 into 
nanometer-sized complexes via electrostatic interactions; 2) Modification of the PPIG4-
siRNA complexes with hydrophilic polymer by conjugation of PEG to PPIG4 amino groups 
on the nanoplatform surface; (3) Conjugation of LHRH peptide to the distal end of PEG 
layer through the maleimide (MAL) groups on the PEG and the thiol groups in LHRH 
peptide. Due to the electrostatic interactions, the positively-charged dendrimer and 
negatively-charged siRNA molecules spontaneously self-assemble into nanoparticles. An 
excess of dendrimers results in encapsulation of siRNA molecules inside of the 
nanoparticles and provides net positive charge on the nanoparticle surface, which in turn 
protect the siRNA against serum nuclease degradation and facilitate cellular internalization.
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Figure 3. 
(A) Basal level of DJ-1 mRNA in non-malignant HUVEC and A2780/CDDP, ES2 and 
IGROV1 ovarian cancer cells measured by quantitative PCR. The intracellular level of DJ-1 
in HUVEC cells was used as a reference and set to 100%. Means ± SD are shown. *p < 0.05 
when compared with HUVEC cells. Inset: Representative Western blot images of DJ-1 
protein and β-Actin expression in HUVEC, A2780/CDDP, ES2 cells and IGROV1 cells. (B) 
Representative agarose gel electrophoresis image of free siRNA (lane 1), PPIG4 (lane 2) and 
siRNA incubated with PPIG4 at the following N/P (PPIG4 amine: siRNA phosphate groups) 
ratios: 0.5 (lane 3), 1 (lane 4), 2 (lane 5), 4 (lane 6), 8 (lane 7) and 10 (lane 8). An efficient 
binding of siRNA molecules with PPIG4 retards their gel electrophoretic mobility and 
prevents siRNA staining by ethidium bromide (lanes 4–8) in comparison to free siRNA (lane 
1). (C) Viability of A2780/CDDP cells after incubation for 48 h with (1) non-modified 
PPIG4-siRNA complexes loaded with scrambled siRNA (1μM), (2) PPIG4-siRNA 
complexes modified with PEG only and (3) PPIG4-siRNA complexes modified with both 
PEG and LHRH peptide (siRNA-NP). Means ± SD are shown. *p < 0.05 when compared 
with cancer cells treated with non-modified PPIG4-siRNA complexes. (D) Size distribution 
profile of siRNA-NP evaluated by dynamic light scattering.
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Figure 4. 
Flow cytometry analysis validates high cellular internalization efficiency of LHRH-targeted 
nanoplatform loaded with DY-547-labeled siRNA after incubation with (A) A2780/CDDP, 
(B) ES2 and (C) IGROV1 ovarian cancer cells for 24 hours. The values on the right side of 
the dashed line indicate percentage of cell population transfected with the fluorescent 
siRNA.
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Figure 5. 
Quantitative PCR analysis (A) and band densitometry analysis of Western blots (B) reveal 
expression of DJ-1 mRNA and corresponding protein levels in A2780/CDDP, ES2 and 
IGROV1 ovarian cancer cells before (basal level) and after treatment with the DJ-1 siRNA-
loaded nanoplatform for 24 h. Band intensities of DJ-1 protein are expressed as the 
percentage of the β-actin band intensity, which was set as 100%. Time point evaluation (24–
96 h) was performed to determine the duration of the siRNA silencing effect on DJ-1 levels 
following a single transfection in all cell lines. Means ± SD are shown. *p < 0.05 when 
compared with untreated cancer cells.
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Figure 6. 
Real time proliferation curves of A2780/CDDP, ES2 and IGROV1 ovarian cancer cells 
treated with media (control), CDDP, DJ-1 siRNA-loaded nanoplatform and combinatorial 
therapy. The DJ-1 siRNA-NP (siRNA = 1μM) and CDDP at the corresponding IC50 
concentrations (A2780/CDDP = 23.6 μM, ES2 = 3.8 μM and IGROV1 = 1.9 μM) were 
added to the appropriate wells 2 h and 24 h, respectively after the cells were seeded in the E-
plate. In case of the combinatorial therapy, the siRNA-NP and CDDP were consequently 
added to the assigned wells 2 h and 24 h, respectively after the cells were seeded in the E-
plate.
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Figure 7. 
Viability of A2780/CDDP, ES2 and IGROV1 ovarian cancer cells after treatment with media 
(control), DJ-1 siRNA-loaded nanoplatform and combinatorial therapy (Combo). Means ± 
SD are shown. *p < 0.05 when compared with cancer cells treated with media.
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Figure 8. 
A wound healing assay was employed to assess the migration of A2780/CDDP, ES2 and 
IGROV1 cells exposed to media (control), CDDP, DJ-1 siRNA-NP and combinatorial 
therapy within 48 h. White lines represents cellular migration border.
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Figure 9. 
The intracellular level of phosphorylated Akt (A) and p53 (B) proteins in A2780/CDDP, ES2 
and IGROV1 cells before after treatment with DJ-1 siRNA-NP for 24 h. Expression of 
proteins was evaluated by band densitometry analysis of Western blots from replicate 
experiments. Band intensities of phosphorylated Akt and p53 proteins are expressed as the 
percentage of the β-actin band intensity, which was set as 100%. Means ± SD are shown. *p 
< 0.05 when compared with cancer cells treated with media. Representative Western blot 
images of phosphorylated Akt, p53 and β-actin proteins expression in the ovarian cancer 
cells before and after exposure to the DJ-1 siRNA treatment are provided.
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Figure 10. 
Cell cycle alteration in A2780/CDDP, ES2 and IGROV1 ovarian cancer cells after treatment 
with CDDP, DJ-1 siRNA-NP or combinatorial therapy. Top panel shows the results of flow 
cytometry analysis using Vybrant® DyeCycle stain. Bottom panel depicts the percentage of 
A2780/CDDP, ES2 and IGROV1 cells in G0/G1 phase of the cell cycle before and after 
treatment with CDDP, DJ-1 siRNA-NP and combinatorial therapy.
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Figure 11. 
(A) The relative increase in caspase-3/7 activity in A2780/CDDP, ES2 and IGROV1 cells 
before after treatment with CDDP, DJ-1 siRNA-NP and combinatorial therapy. The caspase 
activity was set to 100%. (B) The relative intracellular level of reduced glutathione (GSH) in 
ovarian cancer (A2780/CDDP, ES2 and IGROV1) cells before and after treatment with DJ-1 
siRNA-NP for 24 h. The intracellular level of GSH in non-treated HEK293 cells was used as 
a reference and set to 100%. (C) The intracellular level of NRF2 protein in A2780/CDDP, 
ES2 and IGROV1 cells before after treatment with DJ-1 siRNA-NP for 24 h. Expression of 
proteins was evaluated by band densitometry analysis of Western blots. Band intensities of 
NRF2 protein in the various samples are expressed as the percentage of the β-actin band 
intensity, which was set to 100%. Representative Western blot images of NRF2 proteins 
expression in the ovarian cancer cells before and after exposure to the DJ-1 siRNA treatment 
are provided. (D) Relative intracellular level of H2O2 in the ovarian cancer cells after 
treatment with CDDP, DJ-1 siRNA-NP and combinatorial therapy. Cells incubated with 
media were used as the control and intracellular level of H2O2 in these cells was set to 
100%. Means ± SD are shown. *p < 0.05 when compared with cancer cells treated with 
media.
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Figure S1. Representative IC50 curves for CDDP in A2780/CDDP, ES2 and IGROV1 ovarian 
cancer cells obtained from the xCELLigence real time proliferation measurements. Each graph 
consist of eight CDDP concentrations (A2780/CDDP = 100 – 0.8µM, ES2 and IGROV1 = 25 – 
0.2µM) and were analyzed over a 96 h time period. The IC50 curves were calculated and plotted 
using the xCELLigence software where a time dependent sigmoidal dose response curve was 
generated for each cell line.      
 
 
 
 
 
Figure S2. Real time proliferation curves of A2780 ovarian cancer cells treated with media 
(control), and nanoplatform loaded with scrambled siRNA. 
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Figure S3. Level of DJ-1 mRNA in A2780/CDDP, ES2 and IGROV1 ovarian cancer cells 
before (control) and after incubation for 24 h with the constructed nanoplatform containing 1 µM 
scrambled siRNA. 
 
 
 
 
 
 
Figure S4. Flow cytometry analysis demonstrates cellular internalization efficiency of LHRH-
targeted nanoplatform loaded with DY-547-labeled siRNA after incubation with LHRH-negative 
SKOV3 ovarian cancer cells for 24 h. The values on the right side of the red line indicate 
percentage of cell population transfected with the fluorescent siRNA. 
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Figure S5. Level of DJ-1 mRNA in ES2 and A2780/CDDP ovarian cancer cells before and after 
incubation for 24 h with the constructed nanoplatform containing 0.25, 0.5, and 1.0 µM DJ-1 
siRNA. 
 
Figure S6. Expression of DJ-1 protein in tumor tissues. The nude mice bearing subcutaneous 
xenografts of A2780 ovarian cancer cells were intravenously injected with saline (control) and 
the nanoplatform loaded with DJ-1 siRNA (1.1 mg/kg). The harvested tumors were sectioned 
and the sections were incubated with the primary DJ-1 antibody, following the incubation with 
the green fluorescent dye–labeled secondary antibody. All slides were analyzed using EVOS 
Cell Imaging fluorescent microscope. 
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Figure S7. Microscopy images demonstrate caspase-3/7 activity (green fluorescence) in 
A2780/CDDP, ES2 and IGROV1 cells before after treatment with CDDP, DJ-1 siRNA-NP and 
combinatorial therapy. 
 
